We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Seeking Clues to Labcorp (LH) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Read MoreHide Full Article
Wall Street analysts expect Labcorp (LH - Free Report) to post quarterly earnings of $3.49 per share in its upcoming report, which indicates a year-over-year increase of 3.3%. Revenues are expected to be $3.26 billion, up 6.7% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 0.8% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain Labcorp metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts forecast 'Revenues- Diagnostics Laboratories' to reach $2.53 billion. The estimate points to a change of +7.9% from the year-ago quarter.
Analysts predict that the 'Revenues- Biopharma Laboratory Services' will reach $734.73 million. The estimate points to a change of +2.2% from the year-ago quarter.
Based on the collective assessment of analysts, 'Adjusted Operating Income- Biopharma Laboratory Services' should arrive at $111.44 million. The estimate compares to the year-ago value of $109 million.
According to the collective judgment of analysts, 'Adjusted Operating Income- Diagnostics Laboratories' should come in at $409.56 million. The estimate compares to the year-ago value of $386.30 million.
Over the past month, Labcorp shares have recorded returns of -2.9% versus the Zacks S&P 500 composite's +4.5% change. Based on its Zacks Rank #3 (Hold), LH will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Seeking Clues to Labcorp (LH) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Wall Street analysts expect Labcorp (LH - Free Report) to post quarterly earnings of $3.49 per share in its upcoming report, which indicates a year-over-year increase of 3.3%. Revenues are expected to be $3.26 billion, up 6.7% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 0.8% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain Labcorp metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts forecast 'Revenues- Diagnostics Laboratories' to reach $2.53 billion. The estimate points to a change of +7.9% from the year-ago quarter.
Analysts predict that the 'Revenues- Biopharma Laboratory Services' will reach $734.73 million. The estimate points to a change of +2.2% from the year-ago quarter.
Based on the collective assessment of analysts, 'Adjusted Operating Income- Biopharma Laboratory Services' should arrive at $111.44 million. The estimate compares to the year-ago value of $109 million.
According to the collective judgment of analysts, 'Adjusted Operating Income- Diagnostics Laboratories' should come in at $409.56 million. The estimate compares to the year-ago value of $386.30 million.
View all Key Company Metrics for Labcorp here>>>
Over the past month, Labcorp shares have recorded returns of -2.9% versus the Zacks S&P 500 composite's +4.5% change. Based on its Zacks Rank #3 (Hold), LH will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>